Rhythm Pharmaceuticals Inc
$ 98.07
-1.09%
26 Feb - close price
- Market Cap 6,616,880,000 USD
- Current Price $ 98.07
- High / Low $ 103.25 / 95.63
- Stock P/E N/A
- Book Value 2.23
- EPS -3.10
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.86 %
- 52 Week High 122.20
- 52 Week Low 45.91
About
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$141.80
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-02-20 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-22 | 2023-11-07 | 2023-08-01 | 2023-05-02 | 2023-03-01 |
| Reported EPS | -0.82 | -0.75 | -0.81 | -0.72 | -0.73 | -0.69 | -2.35 | -0.7 | -0.76 | -0.82 | -0.92 | -0.75 |
| Estimated EPS | -0.71 | -0.67 | -2.16 | -0.73 | -0.8 | -0.71 | -2.16 | -0.7 | -0.74 | -0.79 | -0.73 | -0.81 |
| Surprise | -0.11 | -0.08 | 1.35 | 0.01 | 0.07 | 0.02 | -0.19 | 0 | -0.02 | -0.03 | -0.19 | 0.06 |
| Surprise Percentage | -15.493% | -11.9403% | 62.5% | 1.3699% | 8.75% | 2.8169% | -8.7963% | 0% | -2.7027% | -3.7975% | -26.0274% | 7.4074% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.79 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RYTM
2026-02-27 04:53:20
Rhythm Pharmaceuticals (RYTM) has filed for a mixed shelf offering, according to a report by Refinitiv. This type of filing allows a company to issue various types of securities, such as common stock, preferred stock, debt securities, or warrants, over a period of time. The article is very brief and does not provide further details on the specific terms or timing of the offering.
2026-02-26 22:53:20
Rhythm Pharmaceuticals Inc. announced that some existing shareholders plan to sell up to 2.4 million shares to meet personal asset allocation goals, which is expected to increase market liquidity but not dilute the company's capital. The company clarified that this is a private financial arrangement by shareholders, not a new share issuance by Rhythm Pharmaceuticals itself.
2026-02-26 14:55:00
Rhythm Pharmaceuticals, Inc. (RYTM) reported a Q4 loss of $0.73 per share, beating the Zacks Consensus Estimate of a $0.79 loss. The company's revenues for the quarter ended December 2025 reached $57.25 million, surpassing the Zacks Consensus Estimate by 3.53%. Despite underperforming the market year-to-date, the stock currently holds a Zacks Rank #3 (Hold).
2026-02-26 12:53:20
Rhythm Pharmaceuticals reported strong financial results for 2025, with IMCIVREE revenue reaching $194.8 million, a significant increase from 2024. The company also narrowed its net loss to $201.9 million and ended the year with $388.9 million in cash, providing an operating runway of at least 24 months. Rhythm is preparing for a potential U.S. launch of IMCIVREE for acquired hypothalamic obesity, pending FDA approval by March 20, 2026, and continues to advance its clinical pipeline.
2026-02-26 12:53:20
Vanguard Group Inc. significantly increased its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) during the third quarter, purchasing an additional 1,407,313 shares to hold a total of 4,996,427 shares valued at approximately $504.6 million. This increase gives Vanguard a 7.52% ownership of the company. Rhythm Pharmaceuticals recently surpassed quarterly earnings and revenue estimates, reporting an EPS of -$0.73 and revenue of $57.25 million, though insiders have recently sold shares.
2026-02-25 16:52:16
Rhythm Pharmaceuticals (NASDAQ: RYTM) is set to release its quarterly earnings, with analysts forecasting an EPS of $-0.78. Investors are keen to see if the company surpasses estimates and provides positive guidance, especially considering a previous earnings miss led to a share price drop. Despite its smaller market capitalization and lower revenue growth compared to industry peers, the company boasts a strong net margin and a healthy debt-to-equity ratio, though its ROE and ROA are below industry averages.
